ATE222489T1 - Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren - Google Patents
Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumorenInfo
- Publication number
- ATE222489T1 ATE222489T1 AT98955056T AT98955056T ATE222489T1 AT E222489 T1 ATE222489 T1 AT E222489T1 AT 98955056 T AT98955056 T AT 98955056T AT 98955056 T AT98955056 T AT 98955056T AT E222489 T1 ATE222489 T1 AT E222489T1
- Authority
- AT
- Austria
- Prior art keywords
- thyroxine
- malignant tumors
- ketone
- treatment
- significant hormonal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/956,711 US5922775A (en) | 1997-10-23 | 1997-10-23 | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
PCT/US1998/022383 WO1999020263A1 (en) | 1997-10-23 | 1998-10-23 | Thyroxine analogues having no significant hormonal activity to treat malignant tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE222489T1 true ATE222489T1 (de) | 2002-09-15 |
Family
ID=25498590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98955056T ATE222489T1 (de) | 1997-10-23 | 1998-10-23 | Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren |
Country Status (7)
Country | Link |
---|---|
US (1) | US5922775A (de) |
EP (1) | EP1024800B1 (de) |
AT (1) | ATE222489T1 (de) |
AU (1) | AU1195499A (de) |
DE (1) | DE69807349T2 (de) |
ES (1) | ES2181298T3 (de) |
WO (1) | WO1999020263A1 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
JP2002507567A (ja) * | 1998-03-25 | 2002-03-12 | ラージ スケール バイオロジー コーポレイション | 血管形成を阻害するための安息香酸誘導体 |
US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
US6326402B1 (en) * | 1998-08-12 | 2001-12-04 | Octamer, Inc. | Methods for treating viral infections using a compound capable of inhibiting microtubules |
US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
US6613534B2 (en) | 2001-03-20 | 2003-09-02 | Wake Forest University Health Sciences | MAP-2 as a determinant of metastatic potential |
CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
MX2007014501A (es) * | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos novedosos que contienen acido fosfinico. |
KR20080035630A (ko) * | 2005-07-18 | 2008-04-23 | 바이파 사이언스 인코포레이티드 | 암의 치료 |
US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
CA2655257A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
WO2008030892A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
US8143447B2 (en) | 2006-09-05 | 2012-03-27 | Bipar Sciences, Inc. | Treatment of cancer |
EP2061479A4 (de) * | 2006-09-05 | 2010-08-04 | Bipar Sciences Inc | Fettsäuresynthesehemmung durch parp-hemmer und behandlungsverfahren damit |
AU2007292302A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing PARP inhibitors and uses thereof |
EP2211854A4 (de) * | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | Verfahren und zusammensetzungen zur behandlung von krebs mit parp-inhibitoren vom benzopyrontyp |
KR20100102609A (ko) | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Parp 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법 |
AU2009212401A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating PARP-mediated diseases |
US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
RU2019114863A (ru) | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
CA3044059A1 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
BR112019016132A2 (pt) * | 2017-02-03 | 2020-04-07 | Univ California | composições e métodos para a inibição de reticulon 4 |
BR112019025659A2 (pt) | 2017-06-05 | 2020-08-25 | Viking Therapeutics, Inc. | composições para o tratamento de fibrose |
US11433074B2 (en) | 2017-06-22 | 2022-09-06 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
EP3687501A4 (de) | 2017-09-29 | 2021-06-23 | Triact Therapeutics, Inc. | Iniparib-formulierungen und verwendungen davon |
AU2019238090A1 (en) | 2018-03-22 | 2020-10-08 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
JP2021534214A (ja) * | 2018-08-24 | 2021-12-09 | ゼニオプロ ゲーエムベーハー | 抗増殖活性を有するフェノキシ(ヘテロ)アリールエーテル |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB643089A (en) * | 1947-10-23 | 1950-09-15 | Glaxo Lab Ltd | Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers |
GB642159A (en) * | 1947-10-23 | 1950-08-30 | Glaxo Lab Ltd | Improvements in or relating to the preparation of diphenyl ethers |
US4724234A (en) * | 1982-09-17 | 1988-02-09 | Therapeutical Systems Corp. | Method for producing oncolysis |
US4816255A (en) * | 1985-07-31 | 1989-03-28 | Ghent William R | Treatment of iodine deficiency breast syndrome |
GB9211415D0 (en) * | 1992-05-29 | 1992-07-15 | Ici Plc | Process for the production of purified terephthalic acid |
US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
-
1997
- 1997-10-23 US US08/956,711 patent/US5922775A/en not_active Expired - Lifetime
-
1998
- 1998-10-23 ES ES98955056T patent/ES2181298T3/es not_active Expired - Lifetime
- 1998-10-23 DE DE69807349T patent/DE69807349T2/de not_active Expired - Lifetime
- 1998-10-23 WO PCT/US1998/022383 patent/WO1999020263A1/en active IP Right Grant
- 1998-10-23 AT AT98955056T patent/ATE222489T1/de active
- 1998-10-23 AU AU11954/99A patent/AU1195499A/en not_active Abandoned
- 1998-10-23 EP EP98955056A patent/EP1024800B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1024800A1 (de) | 2000-08-09 |
US5922775A (en) | 1999-07-13 |
EP1024800B1 (de) | 2002-08-21 |
WO1999020263A1 (en) | 1999-04-29 |
DE69807349T2 (de) | 2003-01-02 |
AU1195499A (en) | 1999-05-10 |
DE69807349D1 (de) | 2002-09-26 |
ES2181298T3 (es) | 2003-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE222489T1 (de) | Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren | |
ATE300292T1 (de) | Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren | |
DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
DE69634900D1 (de) | Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis | |
DE69127175D1 (de) | Antisens-Oligonukleotide zur Behandlung von Krebs | |
DE69736745D1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
ATE347366T1 (de) | Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen | |
DE69839586D1 (de) | Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung | |
ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
DE69532804D1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
ATE249233T1 (de) | Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen | |
NO994330L (no) | Metode for behandling av en tumor | |
DE69902523D1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
NO932101D0 (no) | Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE3854121D1 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
DE59902666D1 (de) | Edelfosin zur behandlung von hirntumoren | |
ATE181240T1 (de) | Verwendung von somatostatinanalogen zur behandlung von melanomen | |
ES2110057T3 (es) | Composicion medicinal que contiene tcf-ii. | |
DE59911556D1 (de) | Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor | |
DE69732851D1 (de) | Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren | |
DE69231465T2 (de) | Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1024800 Country of ref document: EP |